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The Journal of Immunology
Lymphocryptovirus Infection of Nonhuman Primate B Cells
Converts Destructive into Productive Processing of the
Pathogenic CD8 T Cell Epitope in Myelin Oligodendrocyte
Glycoprotein
S. Anwar Jagessar,*,†,‡ Inge R. Holtman,x Sam Hofman,* Elena Morandi,{
Nicole Heijmans,* Jon D. Laman,x Bruno Gran,{ Bart W. Faber,‖ Sander I. van Kasteren,#
Bart J. L. Eggen,x and Bert A. ‘t Hart*,†,x
EBV is the major infectious environmental risk factor for multiple sclerosis (MS), but the underlying mechanisms remain obscure. Patient
studies do not allow manipulation in vivo. We used the experimental autoimmune encephalomyelitis (EAE) models in the common mar-
moset and rhesus monkey to model the association of EBVand MS. We report that B cells infected with EBV-related lymphocryptovirus
(LCV) are requisite APCs for MHC-E–restricted autoaggressive effector memory CTLs specific for the immunodominant epitope 40-48
of myelin oligodendrocyte glycoprotein (MOG). These T cells drive the EAE pathogenesis to irreversible neurologic deficit. The aim of
this study was to determine why LCV infection is important for this pathogenic role of B cells. Transcriptome comparison of LCV-infected
B cells and CD20+ spleen cells from rhesus monkeys shows increased expression of genes encoding elements of the Ag cross-presentation
machinery (i.e., of proteasome maturation protein and immunoproteasome subunits) and enhanced expression of MHC-E and of
costimulatory molecules (CD70 and CD80, but not CD86). It was also shown that altered expression of endolysosomal proteases (cathep-
sins) mitigates the fast endolysosomal degradation of the MOG40–48 core epitope. Finally, LCV infection also induced expression of
LC3-II+ cytosolic structures resembling autophagosomes, which seem to form an intracellular compartment where theMOG40–48 epitope
is protected against proteolytic degradation by the endolysosomal serine protease cathepsin G. In conclusion, LCV infection induces a
variety of changes in B cells that underlies the conversion of destructive processing of the immunodominant MOG40–48 epitope into
productive processing and cross-presentation to strongly autoaggressive CTLs. The Journal of Immunology, 2016, 197: 1074–1088.
E
xperimental autoimmune encephalomyelitis (EAE) is the
best characterized animal model of the human autoim-
mune neurologic disease multiple sclerosis (MS) (1, 2).
Mouse and rat EAE models are frequently used for translational
research into the immunopathogenesis of MS and for the devel-
opment of successful immune-modulatory/-suppressive treatments,
with which the progressive loss of neurologic functions can be
slowed down.
T cells have a core pathogenic role in the EAE model, but it is
unclear whether data obtained in inbred/specific pathogen–free
rodents can be directly translated to the pathogen-educated immune
system of outbred primates (3). In recent years, we investigated the
distinct pathogenic roles of autoaggressive CD4+ and CD8+ T cells
in nonhuman primate models of MS: EAE in the small-bodied
common marmoset (Callithrix jacchus) and the larger-bodied rhesus
macaque (Macaca mulatta). The similarities of these models with
rodent EAE models on the one hand and with MS on the other hand
determine their validity for translational research into the immuno-
pathogenesis of MS (4).
We reported that full clinical evolution of EAE in marmosets
involves two pathogenic pathways. Similar to mouse EAE models,
the pathway that initiates EAE involves the activation ofMHC class
II–restricted CD4+ Th1 and/or Th17 cells. At a later disease stage, a
second pathway is activated that drives EAE progression to irreversible
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neurologic deficits. The latter pathway involves MHC class I/Caja-
E–restricted CD8+CD56+ autoaggressive CTLs specific for myelin
oligodendrocyte glycoprotein (MOG). A similar subset of HLA-E–
restricted CTLs was identified recently in MS lesions (5), albeit
with specificity for myelin basic protein.
In marmoset EAE, T cell autoimmunity against MOG is in-
dispensable for the induction of chronic inflammation (6). The two
immunodominant T cell epitopes are localized in the extracellular
domain: residues 24–36, which activate Caja-DRB*W1201–restricted
CD4+ Th1 cells, and residues 40–48, which activate Caja-E–restricted
autoaggressive CD8+CD56+ CTLs (7–9). Intriguingly, when marmo-
sets were immunized with recombinant human MOG (rhMOG),
representing the full-length extracellular domain (1–125), formulated
with IFA, we observed only T cell activation against the MOG24–36
epitope (10). However, in marmosets immunized with synthetic
MOG34–56 in IFA, we observed activation of CTLs recognizing
the MOG40–48 epitope associated with full-blown clinical EAE
(11). These observations led us to hypothesize that the strongly
pathogenic MOG40–48 epitope is destroyed during processing.
In our search for anAPC type that has the capacity to cross-present
the exogenous MOG epitope via Caja-E to the autoaggressive CTLs,
we found evidence for a crucial pathogenic role for B cells naturally
infected with the EBV-related lymphocryptovirus (LCV) CalHV3
(12). We observed that the opposite clinical effect in relapsing-
remitting MS of an anti-CD20 Ab (ofatumumab) and atacicept, a
soluble antagonist of the B cell cytokines BAFF and APRIL (not
effective), could be replicated in marmoset EAE (13, 14). The
paradoxical clinical effects could be correlated with differential
depletion of CalHV3-infected B cells (15).
In the current study, we investigated Ag presentation by LCV-
infected B lymphoblastoid cells (BLCs) in the marmoset and rhesus
monkey EAEmodels. B cells are professional APCs capable of in vivo
capture and internalization of low-dose exogenous Ags via their BCR
to process the endocytosed Ag in the endolysosomal compartment and
to present peptides via constitutively expressed MHC class II mole-
cules to CD4+ T cells in conjunction with costimulatory molecules
(CD40, CD80/86) (16). However, presentation of exogenous antigenic
peptides via MHC class I to CD8+ T cells in vivo is thought to be
essentially confined to dendritic cells (DCs) (17). Under nonpatho-
genic conditions, B cells cannot exert this function in vivo. However,
we (15, 18) found that infusion of autologous LCV-infected B cells,
prepulsed in vitro with MOG34–56, into healthy rhesus monkeys or
marmosets elicited CD8+ T cell activation in vivo. Therefore, the
hypothesis tested in the current study is that LCV infection of B cells
leads to limited processing of the exogenous encephalitogenic pep-
tide MOG34–56 in such a way that the MOG40–48 epitope remains
available for loading on MHC-E molecules and presentation to core
pathogenic CD8+ T cells in the primate EAE model.
We searched for parallels with a cell type of undisputed cross-
presentation capacity: the CD8a+ mouse DC. The superior capacity
of this DC subset to present exogenous Ag via MHC class I to CD8+
T cells is due to activation of the Ag cross-presentation machinery
and impediment of fast Ag degradation by storage in protease-poor
prelysosomal endosomes (19). Concerning the first issue, we report
a parallel transcriptome analysis of primary and LCV-infected
B cells showing that the virus induces multiple changes associ-
ated with Ag cross-presentation, including increased expression of
MHC class Ib and costimulatory molecules, assembly of immuno-
proteasome, and modulation of endolysosomal protease-expression
profiles. Regarding the second issue, we report that, during the
processing in primary B cells, the MOG40–48 epitope is destroyed
by the endolysosomal protease cathepsin G (CatG). Of special in-
terest concerning the second issue is the observation that LCV in-
fection induces expression of the autophagosome marker L chain 3
(LC3)-II, suggesting activation of the autophagy pathway, which
was implicated in Ag cross-presentation (20). We report that the
CTL epitope MOG40–48 contains an LC3-interacting region (LIR)
motif (21), 44FSRV47, which is destroyed through cleavage at the
Arg46 residue by CatG. We found that substitution of the Arg46
residue by Cit, a modification potentially occurring in LCV-infected
B cells via upregulation of peptidyl arginine deaminase (PAD)2 and
PAD4, protects the 35–51 epitope, as well as the MOG40–48 epi-
tope embedded therein, against degradation.
In summary, we propose that LCV infection of B cells converts
destructive processing of MOG, which is a tolerogenic mechanism
(22), into productive processing enabling cross-presentation of the
pathogenic MOG40–48 epitope to autoaggressive CTLs. We propose
this paradigm as a mechanistic explanation contributing to the well-
established, but poorly understood, association between EBVand MS.
Materials and Methods
Animals and cells
Mononuclear cells (MNCs) were isolated from venous blood (PBMCs) and
spleen cells (SCs) from rhesus monkeys (M. mulatta) and common mar-
mosets (C. jacchus). The monkeys originated from the purpose-bred col-
onies at the Biomedical Primate Research Centre (BPRC). Blood was
collected from sedated animals by venipuncture (femoral vein) and collected
into heparinized vacutainers. Spleens were collected at necropsy of animals
that were sacrificed for reasons not related to this study and immediately
processed for isolation of MNCs. All procedures were reviewed and ap-
proved by the Experimental Animal Care and Use Committee of the BPRC.
Blood MNCs from marmosets were infected with supernatant from the
EBV-producing cell line B95-8 (EBV–B95-8), and blood MNCs from
rhesus monkeys were infected with supernatant of the herpes papio virus
strain S594 (HV papio) (23). B lymphoblastoid cell lines (BLCs) were
generated as previously described (15, 18).
Isolation of MNC fractions and preparation of lysates
MNCs were prepared from blood and spleen as described (12, 24). CD20+
B cells were isolated using MicroBeads (Miltenyi Biotec, Leiden, the
Netherlands), according to the manufacturer’s instructions. The residual
CD202 cell fraction was used as a source of myeloid APCs.
For preparation of cell-free lysates, pelleted SCs (20–50 million) were
frozen at 280˚C and subsequently dissolved in 120 ml of 50 mM citrate
buffer + 5 mM DTT + 0.1% Triton X-100 (pH 5). Subsequently, cells were
sonicated twice (settings in W) for 30 s with 30-s intervals while cooling
on ice, using a Braun sonicator with a 5-mm tip (Braun), to obtain cell-free
lysates. Thereafter, lysates were centrifuged in an Eppendorf centrifuge, at
13,200 rpm, for 20 min at 4˚C. Supernatants were collected, and protein
concentrations were determined by NanoDrop (ThermoFisher Scientific,
Wilmington, DE).
RNA sequencing of primary and LCV-infected B cells from
rhesus monkeys
RNA was isolated from unfractionated rhesus monkey SCs (Mm-SC), SCs
separated into CD20+ or CD202 using an anti-human CD20 mAb and
magnetic bead separation (indicated as CD20+ and CD202 SC), and rhesus
monkey BLCs (Mm-BLCs). Illumina HiSEquation 2000S single-end RNA-
sequencing was performed at the Department of Genetics of the University
Medical Center Groningen (UMCG). FASTQC (25) quality control was
done, and low-quality reads were trimmed with FASTX trimmer (version
0.0.14). TopHat2 (version 0.11.2) (26) alignment was performed using the
Ensembl MMul-1 reference genome obtained from Illumina iGenomes.
Approximately 10 million high-quality uniquely mapped reads were ob-
tained per sample. The reads were quantified using HT-seq count (27) and
imported in R (version 3.2) for differential gene-expression analysis with
EdgeR (28). Gene annotation and gene ontology data for the ensemble data
were obtained using the R BioMart Bioconductor tool (29). The heat map
was generated with log count/million values with heatmap 2. To functionally
annotate the differentially expressed gene lists, Ingenuity Pathway Analysis
(QIAGEN, Redwood City, CA) was used.
Ags
rhMOG was produced in Escherichia coli and purified in house (BPRC), as
described (30). In total, 16 synthetic peptides (Table I) were purchased
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from Peptide 2.0 (Chantilly, VA) and Pepscan (Lelystad, the Netherlands).
Peptides were derived from the MOG sequence of marmosets (Cj-MOGs)
and from the MOG sequence of rhesus monkeys (Mm-MOGs). Sequences
were downloaded from the National Center for Biotechnology Informa-
tion protein database (http://www.ncbi.nlm.nih.gov/protein). Note that the
MOG34–56 peptides from marmoset and rhesus monkey differ at only one
position: a Ser or Pro residue on position 42, respectively. Modifications
included substitution of the positively charged Arg residues on positions 41
and 46 (Arg41 and/or Arg46) for uncharged Cit.
Magnetic bead assay for proteolytic degradation of MOG
peptides
Streptavidin-labeled magnetic beads (Dynabeads; Invitrogen, Carlsbad, CA)
were incubated with biotin/FITC-labeled peptides (peptides B1–B8), ac-
cording to the manufacturer’s instructions. Briefly, after a 2-h incubation
at room temperature, beads were precipitated with a strong magnet to col-
lect the bound peptides. After two washings of the peptide-coated beads
with 160 mM Tris-HCl + 1.6 M NaCl (pH 7.4), they were incubated for
24 h with 40 ml of cell lysates (0.5 mg/ml), 40 ml (CatG) (0.25 mU/ml), or
50 ml of cathepsin H (CatH) (10 ng/ml). After another precipitation step
with the magnet, 50 ml of supernatants was collected into a black 96-well
plate (Greiner Bio-One, Frickenhausen, Germany). The FITC signal pre-
sent in the supernatants was measured with a VICTOR3 Multilabel Counter
model 1420 (PerkinElmer, Waltham, MA) to quantify the amount of peptide
released from the beads as a measure of proteolysis.
Protease inhibitors
To gain insight into the proteolytic mechanism of B cells, we tested the
effect of specific inhibitors of endosomal/lysosomal proteases, including
pepstatin A (0.7 mg/ml), specific for aspartyl proteases (cathepsin D [CatD]
and cathepsin E); cystatin C (0.7 mg/ml), specific for cysteine proteases
(cathepsin B, cathepsin C [CatC], CatH, and cathepsins K, L, and S) and for
aspariginyl endopeptidease; and the multifunctional inhibitor cystatin-
pepstatin inhibitor (0.7 mg/ml) (31). We used the inhibitor 4-(2-aminoethyl)
benzenesulfonyl fluoride hydrochloride (Pefabloc) for the inhibition of serine
cathepsins (32). CatG activity was blocked with 0.1 mM Z-glycyl-leucyl-
phenyl-chloromethyl ketone (CMK) (33). The inhibitor E64 (N-[N-(L-
3-trans-carboxyirane-2-carbonyl)-L-leucyl]-agmatine) (Sigma-Aldrich) is
a cysteine peptidase inhibitor with relative selectivity for cysteine ca-
thepsins (34, 35). We used 10 mM E64 to block cysteine cathepsin (CatH)
activity in cell lysates.
In all experiments, the cell lysates were incubated for 30min at 37˚Cwith
inhibitors at the indicated concentrations prior to the addition of rhMOG
or MOG peptide.
Electrophoresis-based assay for proteolytic degradation of
MOG peptides
rhMOG protein (2 mg) or MOG peptides (10 mg) were incubated with cell
lysates in 50 mM citrate buffer + 5 mM DTT + 0.1% Triton X-100 (pH 5)
in a total volume of 15 ml in Eppendorf tubes. The tubes were incubated
for 3, 24, or 48 h at 37˚C on an Innova 2000 platform shaker set at 40 rpm.
After incubation, 6.25 ml of NuPAGE LDS sample buffer, containing 2.5 ml
NuPAGE Sample Reducing Agent (Invitrogen) and 1.25 ml dH2O, was
added to each sample. Subsequently, 18 ml of each sample was loaded onto a
4–12% Bis-Tris gradient gel (Invitrogen). After running for 60–90 min at 135 V,
the gels were stained for 3–4 h with Simply Blue Safe Stain (Invitrogen) and
destained with dH2O overnight to visualize the protein/peptide bands. A scan
of the gel, which was taken with the ChemiDoc MP Imaging System and
Image Lab software (Bio-Rad, Veenendaal, the Netherlands), was used for
densitometric analysis. Data in the bar graphs are expressed as percentage of
degradation relative to incubations containing rhMOG or MOG peptide only,
which were run on the same gel. Calculations were corrected by subtracting
the background staining and were normalized by measured area (mm2).
CatH activity assay
CatH activity in MNC lysates was determined with a commercially
available assay (BioVision, Milpitas, CA). Briefly, 50 ml of MNC lysate
(200 mg protein/ml) was incubated with CH reaction buffer and CH
R-AFC substrate for 24 h at 37˚C. Color reaction was measured with the
VICTOR3 Multilabel Counter model 1420 (PerkinElmer) at excitation 405
nm/emission 535 nm. Data are expressed as arbitrary counts. As positive
control, 100 ng of active human CatH (BioVision) was used.
CatG activity assay
CatG activity was measured in 50 ml of 200 mg/ml MNC cell lysates in a
total volume of 90 ml of 160 mM Tris-HCl + 1.6 M NaCl + 5 mM DTT
(pH 7.4) and 10 ml of 200 mM Z-Gly-Gly-Arg-AMC substrate (Bachem,
Bubendorf, Switzerland). The total mixture was incubated for 24 h at 37˚C,
and fluorescence was measured with the VICTOR3 Multilabel Counter
model 1420 (PerkinElmer) at an excitation wavelength of 355 nm and an
emission wavelength of 460 nm. As positive control, 5 mU/ml human
CatG (Sigma-Aldrich) was used.
Quantitative PCR
Total RNA was extracted from PBMCs and spleen MNCs, and cDNA was
synthesized for quantitative PCR (qPCR) using primer–probe combinations
(Table II) according to the Universal Probe Library (Roche, Indianapolis,
IN), as previously described (24). Transcript levels were normalized
against the reference gene Abelson (ABL). Only cathepsin mRNA tran-
scripts were analyzed for which reliable primer–probe combinations could
be designed.
Western blotting for LC3
BLCs and splenocytes (106 cells) from C. jacchus and M. mulatta were
incubated overnight at 37˚C with 500 nM bafilomycin (Sigma-Aldrich) to
prevent maturation of autophagic vacuoles by inhibiting fusion between
autophagosomes and lysosomes. Cells were harvested in Eppendorf tubes
and, after a short spin (10,000 rpm), cell pellets were resuspended in 40 ml
of culture media (RPMI 1640 without FCS) and frozen at280˚C for$3 h.
After thawing of cell suspensions, 2 ml of 500 U/ml Benzonase Nuclease
(Merck Millipore, Amsterdam, the Netherlands) was added to degrade all
forms of DNA and RNA, followed by sonification in a sonic water bath (63
30 s with 30-s intervals) while cooling on ice. Six microliters of each sample
was solubilized in 6 ml Laemmli sample buffer containing 0.3 ml of 50 mM
2-ME (Bio-Rad), and 10 ml was loaded on a mini PROTEAN TGX stain-free
4–20% gel (Bio-Rad), which was run for 35 min at 200 V. As a positive
Table I. Peptide sequences
Species Code Peptide Name Sequence
Marmoset/mouse A1 Cj-MOG35–51 MEVGWYRSPFSRVVHLY
A2 Cj-MOG34–51 Cit41 MEVGWY-Cit-SPFSRVVHLY
A3 Cj-MOG34–51 Cit46 MEVGWYRSPFS-Cit-VVHLY
A4 Cj-MOG34–51 Cit41+46 MEVGWY-Cit-SPFS-Cit-VVHLY
Rhesus/human A5 Mm-MOG35–51 MEVGWYRPPFSRVVHLY
A6 Mm-MOG34–51 Cit41 MEVGWY-Cit-PPFSRVVHLY
A7 Mm-MOG34–51 Cit46 MEVGWYRPPFS-Cit-VVHLY
A8 Mm-MOG34–51 Cit41+46 MEVGWY-Cit-PPFS-Cit-VVHLY
Marmoset/mouse B1 Cj-MOG35–51 Biotin-MEVGWYRSPFSRVVHLYK-FITC
B2 Cj-MOG34–51 Cit41 Biotin-MEVGWY-Cit-SPFSRVVHLYK-FITC
B3 Cj-MOG34–51 Cit46 Biotin-MEVGWYRSPFS-Cit-VVHLYK-FITC
B4 Cj-MOG34–51 Cit41+46 Biotin-MEVGWY-Cit-SPFS-Cit-VVHLYK-FITC
Rhesus/human B5 Mm-MOG35–51 Biotin-MEVGWYRPPFSRVVHLYK-FITC
B6 Mm-MOG34–51 Cit41 Biotin-MEVGWY-Cit-PPFSRVVHLYK-FITC
B7 Mm-MOG34–51 Cit46 Biotin-MEVGWYRPPFS-Cit-VVHLYK-FITC
B8 Mm-MOG34–51 Cit41+46 Biotin-MEVGWY-Cit-PPFS-Cit-VVHLYK-FITC
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control, LC3-I and LC3-II were loaded onto the gel, which were provided
together with the anti-LC3 Ab (nanoTools, Teningen, Germany). The Bio-
Rad Trans-Blot Turbo Transfer System was used for blotting the gels onto a
0.2-mm polyvinylidene difluoride membrane (predefined program: Low
MW). Samples were immunoblotted with mouse anti-LC3 (clone 5F10;
nanoTools; dilution 1:200) and with goat anti-GAPDH as loading control
(Novus, Abingdon, U.K.; dilution 1:1,000) in Animal-Free Blocker (Vector
Laboratories, Burlingame, CA) overnight at 4˚C. Rabbit anti-mouse–HRP
(Dako, Glostrup, Denmark; dilution 1:1,000) and mouse anti-goat–HRP
(Jackson ImmunoResearch, Newmarket, U.K.; dilution 1:100,000) in Animal-
Free Blocker were used as secondary Abs. Blots were incubated for 1 h at
room temperature and developed using Clarity Western ECL substrate (Bio-
Rad). A ChemiDoc MP Imaging System and Image Lab software (Bio-Rad)
were used to visualize and quantify the density of the bands. LC3-I and
LC3-II bands were normalized against GAPDH.
Immunofluorescence staining
Mm-BLCs, marmoset BLCs (Cj-BLCs), total marmoset SCs (Cj-SCs), total
Mm-SCs, CD20+ cells, and CD202 cells were washed with PBS, and
cytospins (35,000 cells/slide) were made with the Cytospin 4 Cytocen-
trifuge (ThermoFisher Scientific). Cells were permeabilized for 20 s with
220˚C methanol, air dried, and incubated with the following primary Abs
in PBS/1% BSA for 1 h at room temperature: anti-rabbit PAD2 (1:28;
ab16478; Abcam, Cambridge, U.K.), anti-rabbit PAD4 (1:10; PA5-22317;
Invitrogen), and anti-mouse LC3 (1:250; clone 5F10; nanoTools). Cells
were washed three times with PBS and incubated with the secondary Ab
goat anti-rabbit IgG/FITC (1:200; KPL) or chicken anti-mouse IgG/Alexa
Fluor 594 (1:2000; ThermoFisher Scientific) and with DAPI (1:1000) for
1 h at room temperature in PBS/1% BSA. After four final wash steps with
PBS, coverslips were mounted with the antifade solution Citifluor AF-1
(Agar Scientific, Essex, U.K.). Imaging was performed with a Nikon
Microphot-FXA microscope (Tokyo, Japan) with a 403 lens and a digital
camera (Nikon FX-35DX).
Results
Comparative RNA sequencing of LCV-infected and noninfected
B cells
We performed RNA sequencing to examine changes in molecular
pathways induced in M. mulatta B cells upon immortalization by
experimental infection with the LCV HV papio. The analysis in-
cluded four samples: HV papio–immortalized Mm-BLCs, CD20+
B cells isolated from rhesus monkey PBMCs (Mm-PBMCs), the
residual CD202 PBMC fraction, and unsorted Mm-PBMCs. Three
main analyses were performed: principal component analysis (PCA)
to determine the similarity between the biological replicates for each
condition and the differences among conditions; differential gene-
expression analysis to identify gene differences among conditions;
and Ingenuity Pathway Analysis to identify pathways and gene cat-
egories that are overrepresented in the differential gene-expression
analyses (Fig. 1).
PCA (Fig. 1A) shows close clustering of the expression profiles
of the three biological replicates within each condition, indicating
that they are highly similar, as was expected. The figure also
shows that the first principal component clearly distinguishes Mm-
BLCs from the other samples. The primary aim of the differential
gene-expression analysis was to identify genes that were differ-
entially expressed between HV papio–infected and noninfected
M. mulatta B cells. The most relevant comparison for the current
study is Mm-BLCs versus CD20+ Mm-PBMCs (Fig. 1B). In total,
3108 (1055 + 2053) genes were expressed at a significantly higher
level in Mm-BLCs compared with CD20+ M. mulatta B cells, and
2721 (1087 + 1634) genes were expressed at a significantly lower
level (false discovery rate, p, 0.01; logFC. 1). Furthermore, we
observed a strikingly high overlap between Mm-BLCs and the
CD202 Mm-PBMC fraction (2053 and 1634 up- and downregu-
lated genes in common, respectively).
We were particularly interested in genes related to the Ag
processing and presentation pathways, including the vacuolar route
via endolysosomes and the cytosolic route via the proteasome (17).
Using Gene Ontology categories, all genes that were differentially
expressed between Mm-BLCs and CD20+ Mm-PBMCs were
depicted as a heat map (Fig. 1C). Individual genes with their fold
change (BLC versus CD20+, BLC versus CD202, and CD20+ versus
CD202) are listed in Supplemental Table I.
Gene candidates of interest are CIITA and NLRC5, the master
regulators of MHC class II and MHC class I expression, respectively
(36, 37), which are both downregulated in HV papio–infected
M. mulatta B cells. Several costimulatory molecules were upregu-
lated, such as CD80, TNFSF4 (Ox40L), CD70, and Fas ligand. Others
were downregulated, such as CD40, CD86, and PDCD1 (PD1).
Moreover, a number of cathepsins were differentially expressed.
Table II. Primers with corresponding probes used for qPCR
Species Gene 59–39 Primer 39–59 Primer Probe
ABL CAGAGAAGGTCTATGAACTCATGC GGTGGATTTCAGCAAAGGAG 86
Marmoset CatB GGGAGCCTTCTCTGTGTACG CTCGCCAGTGACATGCTG 4
CatC CGATGTCAACTGCTCGGTTA AATTGCCAAGGTCATCATACG 131
CatD TCCCTGTTCTACCTGAACGTC GTCCACAATGGCCTCACAG 39
CatF CCCAGGACTTGGCTGTGA CGGTTATAGGTAATGACAAAGTTCC 135
CatG TTTGTGCTAACAGCAGCTCAC CTGGGTCCTTTCCCGTCT 60
CatH ATGGGCGAAGACACCTACC TTTCCGGGCTGGAACTTAC 37
CatK CCGGGGTATTGATTCTGAAG GCCTTGCCTGTTGGGTTAT 63
CatL2 CAATGGGGAATACAGCCAAG CAAACCATCACCTGCCTGA 135
CatO CAGCAGATGTGTGGAGGATG GGCTTTCCTTTTATCGCACA 86
CatS GGGTGTGTTACCGAAGTGAAA CCCCCACAGCACTGAAAG 40
PAD2 GCAGGAGAACCTGTACTTCCA GCAGGTCAATGATGTCCTGTT 17
PAD4 TACACTCACCGTCTCCATGC CCACACTGTCTTGGAACAACA 1
Rhesus monkey CatB CAGTGTCCCACCATCAAAGA ATGCAGATCCGGTCAGAGAT 54
CatC TGACTACAAGTGGTTTGCCTTTT TTGTCTCATTGCAGTAAATGGTC 148
CatD AACTGCTGGACATCGCTTG GCAAATGAGGTGCCATTCTT 22
CatE AGCTGCAAAATGCCATCG TGGCACACTCCACAGCATA 58
CatG GCGAGACAACTTTGTGCTGA TCCCGTCTCCGGATATTGT 60
CatH GGGATCATGGGTGAAGACAC CTTTCCAGGCCGGAACTT 37
CatK CTGGGTTTGATAAAACAGGTAACA TGGGCGTAACCATCTACTCC 60
CatL2 CAATGGGGAATACAGCCAAG AACCCATCACCTGCCTGA 135
CatO CTGGGTTTGATAAAACAGGTAACA TGGGCGTAACCATCTACTCC 60
CatW TTTGGGGTGACTCCATTCAG CTCCGATACCCGTAGAGCTG 63
PAD2 CCTCCTGTGTCGGTGTTTG GAAGCAGACCTTCAGGTCACA 22
PAD4 TGAGAGAACATAATTCATTTGTGGA CGGAATGTCGATGATGTCAC 24
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Lastly, a plethora of proteasome-related genes were consistently
upregulated in HV papio–infected M. mulatta B cells.
Taken together, the RNA-sequencing data indicate that HV papio
infection ofM. mulatta B cells induces a unique gene-transcription
profile that clearly differs from noninfected CD20+ M. mulatta
B cells. Differentially transcribed genes include those associated
with Ag presentation and with proteasome and endolysosome
functions; however, the most significantly upregulated pathways
relate to enrichment of cell cycle and cholesterol biosynthesis.
Transcription profiles and activity of cathepsin in APC subsets
Cathepsins are proteases of the endolysosomal pathway that are
centrally involved in the processing of protein Ags (38). We analyzed
mRNA transcript profiles for a number of cathepsins in total PBMCs
or SCs, the CD20+ and CD202 SC subfractions, and BLCs gener-
ated from marmosets and rhesus monkeys. Because we were unable
to isolate sufficient numbers of CD20+ Cj-SCs from the small-bodied
marmosets, we only included unfractionated Cj-PBMCs and Cj-SCs,
as well as Cj-BLCs, from that species.
Isolates of mRNA from unfractionated, CD202 and CD20+ Mm-
SCs, and Mm-BLCs were analyzed by qPCR. Fig. 2A shows that
CatG mRNA is barely detectable in CD20+ Mm-SCs and that
transcript levels did not change postinfection with HV papio. This
contrasts with data obtained in humans: detectable levels of CatG
protease activity were found in CD20+ cells (39). In the CD20+
Mm-SC fraction (i.e., B cells), CatH also attracted our attention
because the mRNA transcript level of this cysteine protease was
highly expressed in M. mulatta B cells but was downregulated
postinfection with HV papio. This downregulation by LCV in-
fection was also observed in the RNA-sequencing analysis. In
addition, we found increased mRNA transcripts of the cysteine
protease CatC in HV papio–infected M. mulatta B cells.
Because the data frommarmoset Cj-SCs and EBV–B95-8–induced
Cj-BLCs essentially mirrored those obtained in the corresponding
fractions from rhesus monkeys, with the exception of CatD and
cathepsins K and O (Fig. 2B), we assume that values obtained for the
other cathepsins in CD20+ and CD202 SC fractions from rhesus
monkeys may be tentatively extrapolated to marmosets.
Proteolytic degradation of rhMOG in SC lysates from
marmosets and rhesus monkeys
We analyzed the degradation of rhMOG in lysates from Cj-SCs and
Mm-SCs to examine potential species-related differences. To this
end, rhMOG was incubated for 3, 24, and 48 h with different doses
of cell lysates. Fig. 3A–C show intact rhMOG as a single band of
619 kDa in the gel. Full degradation of rhMOG with the highest
concentration (5 mg) of Cj-SC lysate was detected after 48 h of
incubation; however, its degradation by Mm-SC lysate was in-
complete under these conditions. The pattern of bands suggests
that rhMOG may be cleaved at different positions in Mm-SCs
FIGURE 1. RNA sequence data. High-
throughput Illumina single-end sequenc-
ing was performed on three replicates of
BLC, CD20+, CD202, and PBMC sam-
ples. (A) PCA was done on the samples,
and the first and second components are
depicted as a scatter plot. (B) Differential
gene-expression analysis was performed
on BLCs versus CD20+ and BLCs versus
CD202, and the number of differentially
expressed genes (false discovery rate ,
0.01, logFC . 1) is depicted as a Venn
diagram. (C) In these differential gene-
expression lists, selected genes associated
with Ag presentation, lysosome, and pro-
teasome are depicted as a sample clustered
heat map with Z-scores across samples. A
list of all genes with their fold change
(BLC versus CD20+, BLC versus CD202,
and CD20+ versus CD202) is shown in
Supplemental Table I.
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compared with Cj-SCs. The observation that degradation is slower
in Mm-SCs than in Cj-SCs, with the persistence of intermediate
degradation products being observed in Mm-SCs, indicates that
processing of rhMOG may be different between rhesus monkeys
and marmosets.
To test whether B cell proteases contribute to the proteolytic
degradation of rhMOG, we incubated the protein with lysates from
the CD202 and CD20+ fractions of Mm-SCs for 3, 24, and 48 h.
Fig. 3D–F show that rhMOG was rapidly and completely de-
graded in lysates from the CD202 fraction of Mm-SCs, whereas
only moderate degradation could be detected in the CD20+
fraction.
Regarding the prominent role of LCV-infected B cells as APCs
in the nonhuman primate EAE models (12), we also tested pro-
teolytic degradation of rhMOG in lysates of BLCs. BLCs were
generated by infecting marmoset and rhesus monkey MNCs with
the relevant LCV (i.e., human EBV–B95-8 and HV papio, re-
spectively). Fig. 3G–I demonstrate that rhMOG is minimally de-
graded in lysates of rhesus monkey or marmoset BLCs, although
some degradation products could be distinguished as smaller
FIGURE 2. qPCR of cathepsin transcripts in MNC subsets from rhesus monkey and marmosets. Total RNAwas extracted from rhesus monkey (A) and
marmoset (B) PBMCs and spleen MNCs. Also, CD20+ and CD202 fractions were isolated from rhesus monkey samples. cDNAwas synthesized for qPCR
using primer–probe combinations (Table II). Transcript levels were normalized against ABL. Data are presented as mean 6 SEM.
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bands in the Cj-BLC incubate at 48 h. These data indicate that,
although B cells are capable of proteolytic degradation of rhMOG,
this activity is nearly completely abolished by infection with LCV.
Delineating the roles of CatG and CatH
Data reported by Burster et al. (39) show a central role for CatG in the
processing of the myelin Ag myelin basic protein in human B cells.
However, the qPCR data in Fig. 2A show high levels of CatG mRNA
in CD202 SCs, whereas it was undetectable in CD20+ SCs. Because
the absence of (active) CatG protein may well explain the different
degree of rhMOG degradation in both fractions, we examined the
effect of the specific CatG inhibitor CMK. Because the qPCR data in
Fig. 2 show that CatH mRNA expression in B cells is downregulated
after LCV infection, we also included CatH in this analysis, a pro-
tease with aminopeptidase and endopeptidase activity that can also
cleave peptides at Arg residues (40, 41). Because a specific inhibitor
of CatH is not available, we used the covalent cysteine cathepsin
inhibitor E64. Note that E64 is not specific for CatH; at the con-
centrations used, it also inhibits the other cysteine cathepsins.
First, we tested the level of CatG and CatH activity in the different
cell lysate preparations using protease-specific assay kits; for vali-
dation purposes, the inhibitors CMK and E64 were included. The
data in Fig. 4A show that considerable CatG activity was detected in
all analyzed cell preparations and that activity could be inhibited to
background level with CMK; E64 had no effect on CatG activity (data
not shown). The highest CatG activity was observed in BLCs from
marmosets and rhesus monkeys and in CD202Mm-SCs. All assayed
cell preparations also tested positively for CatH activity, which could
be inhibited with the nonspecific cysteine cathepsin inhibitor E64;
CMK had no effect in the CatH assay (data not shown). The highest
CatH activity was detected in the lysate of unfractionated Cj-SCs; it
was approximately twice as high as the activity in Mm-SCs.
To confirm the involvement of CatG and CatH in the degradation
of rhMOG, we tested the effect of E64 and CMK on rhMOG deg-
radation in lysates of CD20+, CD202, and unfractionated Mm-SCs.
Fig. 4B and 4C show that the degradation of rhMOG in lysates of
nonfractionated Mm-SCs or CD202 Mm-SCs was only partially inhib-
ited by CMK or E64, whereas the degradation of rhMOG in the CD20+
Mm-SC lysate was reduced to background levels. Interestingly, Fig. 4D
and 4E show that the degradation of rhMOG in the lysate of non-
fractionated Cj-SCs was almost completely suppressed by CMK and E64.
In conclusion, the data indicate an active role for CatG and
probably for CatH in the proteolytic degradation of rhMOG.
Degradation of MOG35–51 in cell lysates of rhesus monkeys
and marmosets
The specificity profile of CatG from rhesus monkeys and mar-
mosets differs. Although CatG from both species has chymotryptic
FIGURE 3. Proteolytic degradation of rhMOG. A
fixed concentration (2 mg/ml) of rhMOG was incubated
for 3, 24, or 48 h with different concentrations (5, 2.5,
and 0.5 mg) of lysates from Mm-SCs and Cj-SCs (A),
Mm-SC CD20+ and Mm-SC CD202 fractions (D), and
Mm-BLC and Cj-BLC lysates (G). After the indicated
time intervals aliquots of the lysates were run on a
4–12% Bis-Tris gradient gel, which was stained with
Coomassie Blue to visualize degradation. For each gel,
the percentage degradation of rhMOG was calculated
as described in Materials and Methods. The percentage
degradation of rhMOG by the different lysates is shown
for Mm-SCs (B), Cj-SCs (C), Mm-SC CD20+ (E),
Mm-SC CD202 (F), Mm-BLCs (H), and Cj-BLCs (I).
Second to last lane contained lysate with OVA as an
irrelevant Ag. OVAwas not degraded and is not shown
in this figure. Data shown are a representative of at
least three replicates.
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activity, cleaving at aromatic residues (Trp, Phe, Tyr), rhesus
monkey and human CatG also have tryptic activity and can cleave
after Lys and Arg residues (42).
The pathogenically dominantMOG epitope 40–48 (YRPPFSRVV)
contains four potential CatG cleavage sites: the two Arg residues at
position 41 and 46 and the aromatic residues Tyr (Y40) and Phe (F44)
(Fig. 5). This was confirmed when we incubated the longer peptide
MOG35–51 with human CatG and analyzed the generated fragments
with mass spectrometry (data not shown). Therefore, we reasoned
that CatG destroys the pathogenically highly important MOG40–48
epitope during processing in B cells.
For the initial analyses of MOG peptide proteolysis we used
magnetic beads coated with MOG35–51 peptides. Alignment of the
peptide sequences from a variety of species ranging from the naked
mole rat to human shows the high conservation of this sequence;
only position 42 is bimorphic and can be occupied by a Ser (S) or
Pro (P) residue (Fig. 5). We first tested whether the presence of a
Ser or Pro residue at position 42 alters the degradation of the MOG
peptide. To this end, we incubated peptide-coated magnetic beads
for 24 h with variable concentrations of lysates from CD20+ and
CD202 Mm-SCs in the presence of cathepsin inhibitors. Fig. 6
shows moderate cleavage of the marmoset peptide (Cj-MOG35–51)
in the CD20+ Mm-SC fraction lysate, which already reached a
plateau at a lysate concentration of 4 mg/ml, whereas degradation of
the rhesus monkey peptide (Mm-MOG35–51) increased in a dose-
dependent fashion. In the CD202 fraction, degradation of the rhesus
monkey peptide (Mm-MOG35–51) was approximately three times
higher than degradation of the marmoset peptide (Cj-MOG35–51).
Proteolytic activity in the CD20+ fraction was reduced to back-
ground levels by the general serine protease inhibitor Pefabloc and
the CatG-specific inhibitor CMK. The other inhibitors exerted no
detectable effect, indicating that the serine protease CatG has an
exclusive role in the degradation of the MOG35–51 peptides in the
B cell lysate. In the CD202 fraction, lysate cleavage was inhibited
by Pefabloc, but not by CMK, indicating that CatG is not involved
but that the peptides are degraded by other serine proteases that
need to be identified.
We used the same assay for testing the proteolytic degradation of
the two MOG peptides in BLC lysates. Fig. 6B shows that the two
MOG peptides (Cj-MOG35–51 and Mm-MOG35–51) are more or
less equally degraded in Mm-BLC lysate and that degradation is
completely suppressed by the inhibitor CMK. Also, the two
peptides are equally degraded in lysate of marmoset Cj-BLCs;
however, in this case, the inhibitor CMK was only partially ef-
fective. The inhibitor E64 had no effect in this assay, indicating
that CatG is the principal protease for degradation of the peptide.
In the next set of experiments, degradation of the MOG peptide
was confirmed on an SDS-PAGE gel. Fig. 7A and 7B show that
about 80% of the Cj-MOG35–51 and Mm-MOG35–51 peptides
was degraded in lysates of total Mm-SCs and of the CD20+ and
CD202 fractions. The inhibitors CMK and E64 were not equally
effective in all conditions. The CatG inhibitor CMK reduced degra-
dation of the Mm-MOG35–51 peptide in the total Mm-SC lysate
more effectively than that of the Cj-MOG35–51 peptide. However, in
the CD20+ SC fraction, the suppressive effect of E64 on the degra-
dation of both peptides was substantially higher than the effect of
CMK. E64 incompletely inhibited the degradation of the Mm-
MOG35–51 peptide in the CD202 fraction lysate, whereas degra-
dation of the Cj-MOG35–51 peptide was completely inhibited. These
observations suggests that the partial inhibitory effect of CMK ob-
served in the Cj-BLC lysate (Fig. 6B) may be due to residual activity
of CatH. Indeed, the CatG inhibitor CMK reduced the degradation
of both peptides in the Cj-SC lysate to ∼50%. In the experiment
depicted in Fig. 7C and 7D, the degradation of both peptides was
tested in unfractionated Cj-SC lysates. The data show that degrada-
tion of the Cj-MOG35–51 peptide was suppressed less effectively by
FIGURE 4. Involvement of CatG and CatH in
rhMOG degradation. (A) Activity measurements of
CatG (left panel) and CatH (right panel) in the indi-
cated cell lysates. Measurements were performed in the
absence or presence of the inhibitors CMK and E64.
Data are presented as mean 6 SEM. Lysates were
prepared from total Mm-SCs, as well as from CD202
and CD20+ cell fractions. (B) Lysates were incubated
with rhMOG for 24 h in the presence or absence of
CMK or E64. (C) Percentage degradation of rhMOG.
(D and E) The same analysis was performed for non-
fractionated Cj-SCs. Data shown are a representative of
at least three replicates. *p , 0.05.
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CMK than was degradation of the Mm-MOG35–51 peptide, whereas
the cysteine cathepsin inhibitor E64 was about equally effective.
Finally, we also tested the proteolytic degradation of the two
peptides in lysates of LCV-infected B cells from the two species.
Fig. 7D and 7E show that the degradation of both peptides is about
equally effective in Mm-BLCs and Cj-BLCs and that the inhibi-
tors CMK and E64 were about equally effective.
In conclusion, the presence of a Ser or Pro residue on position 42
has no clear influence on the sensitivity of MOG35–51 peptide to
proteolytic degradation in B cell lysates. Both assays show a clear
role for CatG in the degradation of the peptide.
Degradation of citrullinated MOG35–51 peptides in cell
lysates
Because CatG is prominently involved in the degradation of rhMOG
in B cells and has a preference for Arg residues at the cleavage site,
we hypothesized that substitution of the Arg41 and/or Arg46 residues
by neutrally charged Cit might affect the degradation of the peptides
in BLC lysates. Fig. 8A shows a major effect of Arg substitution by
Cit on the degradation of the MOG peptides, although the effect
differed remarkably between the Cj-MOG35–51 and Mm-MOG35–
51 peptides. Replacement of the Arg41 or Arg46 residue or both for
Cit did not alter the sensitivity of the Mm-MOG35–51 peptide to
FIGURE 5. Alignment of recombinant MOG sequences. Recombinant MOG sequences encoding from 1 to 125 were aligned for the following species:
human, rhesus monkey, marmoset, mouse, rat, and naked mole rat. The pathogenically relevant T cell epitope in the rhMOG sequence MOG24–36 (MHC
class II/Caja-DRB1*W1201–binding Th1 epitope) is single underlined, whereas the one in MOG40–48 (MHC class I/Caja-E–binding NK-CTL epitope) is
double underlined. The two epitopes are located in close proximity within the highly conserved sequence 21–58. The only difference between the sequence
in mouse/marmoset/rat versus rhesus monkey/human MOG is a substitution of proline (P) by a serine (S) at position 42 (indicated in green). The Arg (R)
residues, which can be citrullinated by posttranslational modification, are indicated in red. The pound sign (#) marks the only N-glycosylation site at the
asparagine (N) at position 31.
FIGURE 6. Degradation of bead-coated Mm-MOG35–51 and Cj-MOG35–51. Peptides that were labeled at the N terminus with biotin and at the
C-terminal end with FITC were coated on magnetic beads via streptavidin. The peptide-coupled beads were incubated for 24 h at 37˚C in lysates of CD20+
(upper panel) and CD202 (lower panel) SC fractions from rhesus monkeys (A) or Mm-BLCs (upper panel) and Cj-BLCs (lower panel) (B). The indicated
inhibitors were tested at the optimal concentration. Depicted is the release of FITC in arbitrary units (AU) from the peptide into the supernatant, as a
measure of proteolytic activity.
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degradation, whereas the Arg46Cit substitution reduced the sensi-
tivity of the Cj-MOG35–51 peptide to degradation. It can also be seen
that the CatG inhibitor CMK had less effect than the CatH inhibitor
E64 on the proteolytic degradation of the Mm-MOG34–56 Cit41 or
Mm-MOG34–56 Cit46 modifications in the total spleen or CD202 SC
lysate. The two inhibitors were equally effective in the CD20+ SC ly-
sate. Similar effects were observed with the lysate of Cj-SCs (Fig. 8B).
We then tested the degradation of MOG35–51 peptides in lysates
of LCV-infected B cells from rhesus monkeys (Mm-BLCs) or
marmosets (Cj-BLCs), with or without inhibition of CatG (CMK)
or CatH (E64). The results in Fig. 8C show that substitution of
the Arg46 residue for Cit made the Cj-MOG35–51 peptide resistant
to degradation, whereas the Arg41 for Cit substitution had no de-
tectable effect. The Arg46 for Cit substitution had no effect on the
proteolytic degradation of the Mm-MOG35–51 peptide.
In conclusion, the combination of the Arg46 to Cit substitution
with the presence of a Ser42 residue made the complete MOG35–51
peptide resistant against proteolytic degradation in all tested lysates.
Autophagy induction in LCV-infected B cells
Citrullination of antigenic peptides is a physiological process that
can take place in autophagosomes of APCs (43). If citrullination of
the encephalitogenic MOG34–56 peptide played any role in the
conversion of destructive processing to productive processing of
the MOG40–48 epitope in LCV-infected B cells, we would expect
to observe induction of autophagy and concomitant induction of
PAD enzymes by the virus.
In LCV-infected and uninfected cells we analyzed the expression
of two PAD genes that are involved in the citrullination of Ag:
PAD2 and PAD4. Fig. 9A and 9B show that PAD2 and PAD4,
respectively, are highly expressed in Cj-BLCs compared with SCs
and fractionated SCs. Interestingly, the PAD2 and PAD4 transcript
levels were lower in Mm-BLCs than in Cj-BLCs.
Regarding the relevance of autophagy for cross-presentation by
DCs (20), the capacity of the autoantigen to associate with auto-
phagosomes may be a rate-limiting step. The microtubule-associated
LC3, and, in particular, the phosphatidylethanolamine-linked iso-
form LC3-II, is an accepted phagophore/autophagosome marker.
LC3-II expressed on the inner membrane of the autophagosomes
serves as a docking molecule for cargo binding. We noticed that the
Arg46 residue is located in a sequence that is a putative LIR motif:
[W/Y/F]xx[L/I/V], where x can be any amino acid (21). The motif
expressed in the Cj-MOG40–48 epitope is YRSPFSRVV (21).
We reasoned that if autophagy is involved in autoantigen cross-
presentation by LCV-infected B cells, infection with the virus should
induce the expression of autophagosomes. This was investigated
FIGURE 7. Mm-MOG35–51 and Cj-
MOG35–51 degradation by different cell
lysates. (A) Cj-MOG35–51 and Mm-
MOG35–51 peptides were incubated for
24 h at a fixed concentration (10 mg/ml)
with total SC lysate and with CD20+ and
CD202 spleen fractions from rhesus
monkeys. (B) Percentage degradation of
the MOG peptides. Total Cj-SCs (C and
D) and Cj-BLCs and Mm-BLCs (E and
F) were tested under the same condi-
tions. All lysates were incubated in the
presence or absence of the inhibitors
CMK and E64. Data shown are a rep-
resentative of at least three replicates.
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at the protein and cellular levels. On Western blot, the expression of
LC3-I and LC3-II was determined. Fig. 9C and 9D reveal high ex-
pression of LC3-II (614 kDa) in Cj-BLCs. The cell fractions derived
from the spleen and Mm-BLCs showed only a marginal expression of
LC3-II compared with Cj-BLCs. A similar pattern was observed for
LC3-I, although in Mm-BLC, the expression of LC3-I is slightly
FIGURE 8. Citrullination prevents degradation of MOG peptides. MOG35–51 peptides derived from the marmoset and rhesus monkey sequence were
synthesized; Arg at positions 41 and/or 46 were replaced by Cit. The peptides were incubated for 24 h at a fixed concentration (10 mg/ml) with total SC
lysate, CD20+ and CD202 spleen fractions from rhesus monkeys (A), marmoset total SCs (B), or Mm-BLC lysates and Cj-BLC lysates (C). All lysates were
incubated in the presence or absence of the inhibitors CMK and E64. The graphs represent the percentage degradation of the indicated peptide. Data shown
are a representative of at least three replicates. SDS-PAGE gels are shown in Supplemental Fig. 1.
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higher than LC3-II. The expression of LC3-I was slightly higher than
LC3-II in Mm-BLCs. Protein expression of PAD2, PAD4, and LC3
was confirmed on Mm-BLCs and Cj-BLCs with immunofluorescence
staining (Fig. 9E). This staining was also performed on total Mm-SCs,
CD20+, CD202, and total Cj-SCs. As expected, these cells were
smaller than BLCs and it seemed that relatively fewer PAD2+, PAD4+,
and LC3+ cells were observed compared with BLCs.
Discussion
One of the unresolved mysteries in MS is its association with EBV
infection (44). Mechanistic studies need to help explain how a
virus that infects .90% of the adult human population can be the
trigger of a relatively uncommon disease, such as MS, on the
appropriate genetic susceptibility background. The observation
that EBV is also significantly associated with the risk for systemic
lupus erythematosus might suggest that the association is based on
generic, in addition to disease-specific, mechanisms. To find an
explanation, we used our EAE models in marmosets and rhesus
monkeys, nonhuman species that are naturally infected with EBV-
related LCV (23).
Collectively, previous data obtained in the marmoset model and
replicated in part in rhesus monkeys (reviewed in Refs. 12, 45)
show that LCV-infected B cells have a central pathogenic role in
the activation of highly pathogenic MHC-E–restricted effector
memory cytotoxic T cells that, upon activation with the MOG34–
56 peptide (core epitope 40–48), can elicit MS-like pathology and
disease. Notably, similar autoaggressive CTLs were found in MS
lesions, where they seemed to be engaged in cytotoxic interactions
with HLA-E+ oligodendrocytes (5). The concept that LCV-infected
B cells are essential APCs in the immunopathogenic process is
supported by the potent clinical effects of depleting anti-CD20
mAbs in MS, which were replicated in the marmoset EAE model
(46). These effects are rapid and most likely are not mediated by
interference with Ab production, considering that mature plasma
cells do not express CD20.
B cells are efficient APCs for CD4+ T cells, because they can
capture exogenous Ag at low concentrations via their clonal BCR
and then process it in their endolysosomal compartment and
present epitopes via MHC class II molecules to CD4+ T cells (16).
For presentation of an exogenous Ag via MHC class I molecules
to CD8+ T cells, the Ag needs to be translocated from the MHC
class II loading compartment to the MHC class I loading com-
partment. However, B cells seem to be less equipped for presen-
tation of exogenous Ag via MHC class I, a capacity known as Ag
cross-presentation (47), at least in the absence of innate immune
stimulation (48). Most insight into the mechanisms underlying Ag
cross-presentation comes from studies in DCs (17). The CD8a+
mouse DC seems particularly well-equipped for this task (19).
As a basis for our study, we assumed that, analogous to the situa-
tion in CD8a+ mouse DCs, LCV infection might endow B cells
with cross-presentation capacity when at least two requirements are
fulfilled: activation of the cross-presentation machinery and pro-
longation of the half-life of the CTL epitope.
Activation of the cross-presentation machinery includes immuno-
proteasome induction for processing of the Ag and induction of
costimulatory molecules. The RNA-sequencing data presented in
this article show that LCV infection of rhesus monkey B cells in-
duced expression of genes encoding several immunoproteasome
elements, supporting the idea that functional immunoproteasomes
are formed in LCV-infected B cells. In this study, LCV-infected
B cells of rhesus monkeys were well able to induce Ag-specific
T cell responses in vivo (18). Hence, we expected to find relevant
expression of costimulatory molecules. The RNA-sequencing data
show marked mRNA transcript upregulation for CD70 and CD80,
whereas mRNAs encoding CD86 and CD40 were reduced. It is of
note that CD80 binds preferentially with CTLA4, whereas CD86 is
the preferred ligand of CD28 (49). This implies that LCV-infected
B cells suppress the activation of naive T cells; however, the con-
stitutively expressed CD70 molecules on mouse DCs relay strong
in vivo activation signals to T cells via homodimeric CD27 recep-
tors (50). We reported previously that CD27 is expressed by auto-
aggressive MOG34–56–specific CTLs induced in the marmoset
EAE model (9). Ligand binding to CD27 complements CD28 in
determining the size of CD8+ effector memory T cell populations
(51). With regard to soluble costimulation factors, we observed that
expression of IL-23 mRNA, but not IL-12 mRNA, is highly in-
creased; this is compatible with the observation that autoaggressive
CTLs express IL-17A as a signature cytokine (11).
Prolongation of the half-life of the CTL epitope
An important condition for Ag cross-presentation is that fast
proteolytic degradation of the Ag in the endolysosomal com-
partment is suppressed to enable translocation to the MHC class I
loading pathway. Indeed, prolongation of the Ag’s half-life favors
cross-presentation (52). The data presented in this article indicate
that, as a consequence of LCV infection, destructive processing of
the epitope in B cells is converted into productive processing. To
our knowledge, the term “destructive processing” was first coined
by Manoury et al. (22) as a mechanism used by thymic APCs to
prevent activation of autoreactive T cells.
A key observation is that activation of T cells against the CD4+ T
epitope 24–36 is clearly detectable in marmosets immunized with
rhMOG/IFA, whereas activation of T cells against the CTL epi-
tope 40–48 was undetectable (10). Nevertheless, the induction of
robust encephalitogenic CTL activation in marmosets immunized
with MOG34-56/IFA showed that CTLs against the 40–48 epitope
are present in the repertoire and can be activated (11). Because a
core-pathogenic role for B cells as APCs could be demonstrated in
the latter model, we hypothesized that the immunizing MOG34–
56 peptide may be rescued from proteolytic degradation when the
B cells are infected with the EBV-related LCV CalHV3 (12).
The current study shows that rhMOG is rapidly degraded in cell-
free lysates of rhesus monkey and marmoset SCs. Although the
strongest proteolytic activity was located in the CD202 fraction,
which contains the myeloid APCs, considerable activity was also
found in the CD20+ fraction, which contains the B cells. The activity
in BLCs was even lower than in untransformed B cells. Using a
protease inhibitor of defined specificity (CMK), we found a domi-
nant role for the serine protease CatG in the proteolytic degradation
of rhMOG. Although low transcript levels of CatG mRNA in B cells
were measured with qPCR, the enzyme-activity assays show high
activity in B cell lysates. Burster et al. (39) reported a similar dis-
crepancy for CatG in the human system. As an explanation, it was
proposed that B cells take up exogenous CatG (e.g., produced in
myeloid APCs) (53), although this is not a satisfactory explanation
for the high CatG activity observed in the LCV-transformed B cell
lines. Because CatG is transcribed as proform, the activity could be
due to variations in activation and deactivation of the bioactive en-
zyme (54). We also observed inhibition of rhMOG degradation by
the cysteine protease inhibitor E64. It is unclear whether this effect
can be attributed to the inhibition of CatH, because E64 is a general
cysteine protease inhibitor that also inhibits CatC, which is the ac-
tivator of serine cathepsins, including CatG. The two inhibitors were
strongly effective in lysates of rhesus monkey SCs but were only
moderately effective in lysates of marmoset SCs. Both inhibitors
were also fully effective in the CD20+ B cell fraction of rhesus
monkey SCs. The observed species differences might be attributed,
in part, to the specificity difference of CatG from marmosets and
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rhesus monkeys. Although CatG of marmosets has a mouse-like
narrow specificity for aromatic (chymotryptic) cleavage sites (Trp,
Phe, Tyr), a double mutation in the specificity-determining residues
(Ala-189-Ser and Glu-226-Ala) broadens the activity of rhesus
monkey and human CatG to basic (tryptic) cleavage sites (e.g., Arg
and Lys) (42).
FIGURE 9. Expression of PAD and LC3 in LCV-infected B cells. Total RNAwas extracted from different cell lysates to determine expression of mRNA
encoding PAD2 (A) and PAD4 (B) by qPCR. Transcript levels were normalized against the reference gene ABL. Median of each cell population is shown.
(C) Cell lysates were immune-blotted for LC3 and GAPDH as loading control. As positive controls, Abs against LC3-I and LC3-II were run along with the
other samples. (D) The density of the LC3-I and LC3-II band in (C) is related to the GAPDH band. (E) Immunofluorescence staining was performed with
rhesus monkey cells (left panel) and marmoset cells (right panel) with anti-PAD2, anti-PAD4, and anti-LC3. Original magnification 3400. *p , 0.05,
**p , 0.001, Cj-BLC/Mm-BLC versus other cell subsets, Mann–Whitney U test.
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To test the proteolytic degradation of the pathogenically dominant
Mm-MOG34-56 peptide we used the shorter peptide MOG35-51 to
avoid interference of the Arg residue at position 52, which is outside
the epitope of interest (residues 40–48). The reported in vitro data
show that native Mm-MOG35-51 peptide is rapidly degraded in cell-
free lysates of noninfected and LCV infected B cells of rhesus
monkeys as well as in LCV-infected B cells of marmosets. Again, a
dominant role of the endolysosomal protease CatG in the degrada-
tion of Mm-MOG35-51 was observed. Interestingly, substitution of
the Pro42 residue for Ser and the Arg46 residues for Cit conferred
complete resistance of the MOG35-51 peptide to proteolytic deg-
radation in the rhesus monkey cell lysates. Substitution of the Arg41
residue for Cit had no detectable effect. How can this be explained?
The alignment of MOG extracellular domain sequences (Fig. 5)
shows that, in a wide range of mammalian species, a Pro residue is
present at position 42, whereas a Ser is present at this position
only in rat, mouse, and marmoset MOG. Data obtained from mice
show that the presence of a Pro or Ser residue on position 42 has a
strong influence on the encephalitogenic potency of the MOG34–
56 peptide (55). The Arg to Cit substitution is a physiologically
relevant modification of antigenic peptides, mediated by the enzyme
PAD (43), which can occur in stressed B cells, such as those infected
by LCV. The investigators claim that citrullination by PAD occurs in
autophagosomes. It is well-documented that LCV infection of B cells
induces autophagy (56). Consistent with this notion, our RNA-
sequencing data showed increased expression of autophagy-related
genes, such as beclin1, ATG5, and ATG12, in LCV-infected B cells
of rhesus monkeys. Moreover, we show that the autophagosome
marker LC3-II is increased in LCV-infected B cells of rhesus monkeys.
Autophagosomes are implicated in cross-presentation (20). On
the basis of the data presented in this article, we propose that they
are also engaged in the protection of MOG peptide against destructive
processing. We assumed that, for association of the MOG35–51
peptide with LC3 molecules in the inner concave surface of growing
autophagosomes, the peptide should contain a LIR motif. The con-
sensus sequence of LIR motifs is [W/Y/F]xx[L/I/V], where x can be
any amino acid (21). In addition to this core motif, the presence of an
acidic residue (E, D, S, T) close to the N-terminal site of the LIR
motif is important. Using this algorithm, we scanned the rhMOG
sequences of marmoset and rhesus monkeys and found three poten-
tial LIR motifs: residues 3–6 (FRVI), 44–47 (FSRV), and 118–122
(FYWV). The 44FSRV47 LIR motif is encompassed within the
pathogenically relevant MOG40–48 epitope. In the marmoset MOG
sequence, it is preceded by Ser42, which contains the favorable Ser42
residue for LC3 association. Because the CatG cleavage site Arg46
is inside the LIR motif, we speculate that substitution of the Arg46
residue for Cit prevents cleavage of the LIR motif by CatG.
In conclusion, based on the results of this study we propose a
physiological role for B cells in the protection against autoim-
munity in MS. They take up autoantigens and neutralize them via
destructive processing; in this way, activation of autoaggressive
CD8+ T cells is avoided. By infection of B cells with LCV, this
protective mechanism is converted into productive processing of
the autoantigen, which enables the activation of autoaggressive
T cells. The proposed underlying mechanism is that, as a result of
several cell-biological changes induced in the B cells, in particular
the formation of autophagosomes with which the encephalitogenic
Ag may associate, the CD8+ T cell epitope is protected against
degradation and remains available for cross-presentation.
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